N/A
N=42
Effect of Levodopa on Postural Motor Learning in Parkinson Disease
Parkinson Disease
Bottom Line
View on ClinicalTrials.gov: NCT02239978 ↗Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Feb 2017
Primary outcome: Primary: Change in Movement of Center of Mass (COM) After Postural Perturbation — 0.31; 0.28; 0.32; 0.26 meters
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Postural perturbation (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Jan 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Movement of Center of Mass (COM) After Postural Perturbation |
0.31; 0.28; 0.32; 0.26; 0.23; 0.31 | — |
| PRIMARY Change in Steps After Postural Perturbation |
2.22; 2.03; 2.09; 1.92; 1.15; 2.05 | — |
| SECONDARY Change in First Step Length |
0.18; 0.25; 0.21; 0.20; 0.27; 0.21 | — |
| SECONDARY Cortical Excitability |
40.57; 40.71 | — |
Summary
The primary goal of this project is to gain a better understanding of whether and how levodopa (a common anti-Parkinson disease medication) alters postural motor learning in people with Parkinson disease. A secondary goal is to assess whether motor cortical excitability, measured via Transcranial magnetic stimulation, is related to postural motor learning.
Participants with Parkinson disease will complete between 50 and 100 postural perturbations (via support surface translations), ON and OFF their dopamine replacement therapy (i.e. levodopa). Adaptation of responses to these perturbations will be tracked. Participants will also undergo transcranial magnetic stimulation to capture cortical excitability of the brain (in particular the motor cortex). Cortical excitability will be correlated to adaptation of stepping (i.e. postural motor learning) ON and OFF levodopa. Investigators will also capture postural motor learning and cortical excitability in age-matched healthy adults.
Investigators hypothesize that dopamine will have a negative effect on postural motor learning, and the cortical excitability will be correlated to postural motor learning.
Eligibility Criteria
Inclusion Criteria
- Between 18 and 90 years of age.
- Individuals with Parkinson Disease
- Healthy adults age-matched to PD participants
- Participants with PD will be currently taking dopamine replacement (i.e. Levodopa)
Exclusion Criteria
All subjects exclusion criteria:
- Deep brain stimulation
- Recent (within 6 months) orthopedic injuries influencing standing or balance
- Inability to stand independently
Transcranial magnetic stimulation exclusion criteria (for the subset of individuals taking part in the Transcranial Magnetic Stimulation portion of the study):
- History of epilepsy or currently taking any epileptic medication,
- History of seizures
- Family history of epilepsy or seizures
Data sourced from ClinicalTrials.gov (NCT02239978). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.